Navigation Links
CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies

LOS ANGELES--(BUSINESS WIRE)--Apr 4, 2007 - CytRx Corporation (NASDAQ:CYTR) today announced positive results of additional animal stroke studies indicating that CytRx's lead drug candidate arimoclomol significantly accelerated the recovery of sensory and motor function in an experimental rat model of stroke, even when treatment was withheld as long as 48 hours after stroke was induced. These data confirm and expand upon preclinical data announced by CytRx in December 2006. Orally-administered arimoclomol is currently in clinical evaluation as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). Based on these impressive results, CytRx will begin planning a potential Phase II clinical trial with arimoclomol in stroke patients.

"These new animal results show that arimoclomol has the potential to help patients recover from the devastating effects of stroke even if the drug is administered well after the actual stroke event," said CytRx President and CEO Steven A. Kriegsman. "We believe this represents a unique advantage of arimoclomol compared with other stroke drug candidates. If efficacious in stroke patients, it would represent a major breakthrough in improving their quality of life. Furthermore, arimoclomol's flexibility for delayed intervention may allow substantial penetration into the $58 billion stroke market because the 'race' to get the patient to an emergency room for treatment may not significantly limit its use, unlike other potential stroke drugs."

In the present study, stroke was induced in rats by blocking blood flow to parts of the brain causing cerebral oxygen deprivation. The rats then received an oral dose of arimoclomol or control substance daily for 35 days, beginning either 6, 12, 24 or 48 hours after stroke was induced. Recovery from stroke was measured by monitoring sensory motor skills. While motor skills declined dramatically in all study rats i
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
2. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
3. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:9/17/2014)... MUMBAI, India , September 17, 2014 ... TRPA1 antagonist, GRC 17536, has shown positive data in ... with painful diabetic neuropathy , ... Transient Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 ... blind, placebo controlled, multi-centre, proof of concept study conducted ...
(Date:9/17/2014)... Texas , Sept. 17, 2014  Lightbeam ... Direct Accountable Care Organization (Physician Direct ACO) to ... their physicians in providing better care while reducing ... Physician Direct Accountable Care Organization ... Network Services (OPNS). The OPNS mission is to ...
(Date:9/17/2014)... 2014 According to a new ... Battery, Memory Device, Display, & Microprocessor/MCU), by Application (Imaging, ... by Geography - Global Forecast to 2020", published by ... expected to reach $56.50 Billion by 2020, growing at ... Browse 235 market data Tables and 71 Figures ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4
(Date:9/17/2014)... 2014 North Central Surgical Center is ... awards for their top-notch services. The hospital was the ... and GYN surgery. , Hospital-wide, North Central was the ... have received this award for two years in a ... percent in the nation for Patient Safety in 2014 ...
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- A blood ... could provide doctors with a better assessment of the ... If used routinely, this blood test could ... working and actually begins promoting tumor growth, the researchers ... given to patients with advanced prostate cancer and often ...
(Date:9/17/2014)... York, New York (PRWEB) September 17, 2014 ... filings involving the Conserve line of metal-on-metal hip ... now underway in U.S. District Court, Northern District ... an updated Case List issued by the U.S. ... 2014, at least 397 product liability claims have ...
(Date:9/17/2014)... September 17, 2014 Why are Asian Americans at ... Americans, and prone to develop the disease at lower ... in the transition from traditional high-fiber, low-fat Asian diets ... for those of Asian heritage, says George King, M.D., ... Diabetes Center and the senior author of the study. ...
(Date:9/17/2014)... The in vitro diagnostics (IVD) marketplace ... focusing on molecular diagnostics for conditions such as infectious ... The IVD market value is projected to be worth ... The major drivers of the market’s growth include the ... evidenced by the explosion for raid and minimally-invasive diagnostic ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... , , , , , , ... (NYSE: MR ), a leading developer, manufacturer and,marketer ... annual general meeting of shareholders held in Hong Kong on,December ... Mindray Medical International,s shareholders approved the,re-election of directors Mr. Xu ...
... nutrition but not physical activity needs, study finds , ... providers meet nutrition standards but don,t give children enough ... in front of the TV, a new study contends. ... 300 home-based child-care providers who looked after children ages ...
... ... a family secret and its shattering consequences, won two prestigious honors: a place on ... one of only 20 to receive the coveted award. , ... Washington, DC (PRWEB) December 18, 2009 -- ...
... , , BIRMINGHAM, Ala., Dec. 18 HealthSouth Corporation (NYSE: ... J.P. Morgan Healthcare Conference in San Francisco on Jan. 11-14, 2010. ... speaking on Monday, Jan. 11, 2010 at 11:30 a.m. PST. The ... http://investor.healthsouth.com by clicking on an available link. , ...
... , WASHINGTON, Dec. 18 Since 1984, Demographic and ... U.S. Agency for International Development (USAID), has collected and ... decision makers to plan, monitor, and evaluate population, health, ... conduct some 260 surveys in over 90 developing countries. ...
... Atyical response to self-relevant thoughts may help explain interpersonal ... brains of autistic people are less active than expected ... helps explain autism-related social difficulties, say British researchers. , ... 66 males, half of whom had autism, while they ...
Cached Medicine News:Health News:Mindray Medical International Limited Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting 2Health News:Kids in Home-Based Day Care Lack Exercise 2Health News:Nonfiction Book on Family Secrets Wins Two Prestigious Honors 2Health News:Nonfiction Book on Family Secrets Wins Two Prestigious Honors 3Health News:Nonfiction Book on Family Secrets Wins Two Prestigious Honors 4Health News:HealthSouth to Present at J.P. Morgan Healthcare Conference 2Health News:USAID Celebrates 25 Years of Demographic and Health Surveys 2Health News:Brain Imaging Sheds Light on Social Woes Related to Autism 2
... 6000 lets you manually ... precise positioning. The superior ... immediate and exact positioning ... making it especially effective ...
The Total Toe System offers a new generation in first metatarsophalangeal joint reconstruction....
The Acumed Great Toe System is a two-piece non-constrained implant for the first MP joint. The system was developed to provide ease of use for the surgeon, combined with precise instrumentation and a...
The design features of the Mini Lag Screw System simplify the screw fixation by reducing possible sources of error, reducing instrumentation, and decreasing the time of fixation....
Medicine Products: